January 6, 2023. For the first Eye on the Cure episode for 2023, host Ben Shaberman highlights some of the promising clinical advancement made in therapy development over the last year. His recap includes discussions of emerging treatments from: SparingVision, Atsena Therapeutics, Alkeus, Belite, Apellis, Iveric Bio, MeiraGTx, AGTC, 4DMT, and Opus Genetics, which, after the recording of the episode, reported its acquisition of rights to gene therapies for Best disease and RP (RHO).

December 16, 2022. Rando Allikmets, PhD, from Columbia University, talks to host Ben Shaberman about his remarkable and serendipitous discovery more than two decades ago of ABCA4, the gene associated with Stargardt disease. The breakthrough changed the trajectory of his career, changed the landscape of Stargardt disease research, and led to the development of gene therapies and visual cycle modulators.

The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa

The LCA5 gene therapy will be the first emerging Opus treatment to move into a human study

December 2, 2022. Host Ben Shaberman interviews Sue Bramhall who launched Mind's Eye Travel to host journeys around the world for people with vision loss. Affected with RP, Sue channels her passion for travel and planning to organize group adventures that include great eating, tactile experiences, and other non-visual experiences for her guests. Sighted guides also join the excursions to help along the way. Upcoming trips include Europe, Africa, and New Zealand. Learn more at www.MindsEyeTravel.com.

November 18, 2022. Kenji Fujita, MD, chief medical officer at Atsena Therapeutics, talks to host Ben Shaberman about retinal disease gene therapies including positive results from his company's gene therapy clinical trial for people with Leber congenital amaurosis 1 (GUCY2D mutations) as well as Atsena's emerging gene therapies for X-linked retinoschisis and Usher syndrome type 1B.

The company is seeking a partner to move the LCA10 program forward

November 4, 2022. In this episode of Eye on the Cure, host Ben Shaberman talks with LambdaVision's Nicole Wagner, PhD, and Jordan Greco, PhD, about the company's emerging protein-based artificial retina, the promise it holds for restoring vision, and the low-gravity, manufacturing experiments that have been conducted at the International Space Station.

A blinding disease diagnosis can be overwhelming. Some good advice can go a long way. Do you have any advice for someone newly diagnosed? #ShareYourVision

Ask. Questions. #ShareYourVision to tell others how to best support you.

Learn more about how you can #ShareYourVision at: www.FightingBlindness.org/ShareYourVision